|
24 Jun 2021 |
Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity in People with Metastatic, PDL1-High Non-Small Cell Lung Cancer at First Interim Analysis of Arcus Biosciences’ Randomized Phase 2 ARC-7 Study
|
|
23 Jun 2021 |
Alfasigma acquires the European license for bentracimab from PhaseBio
|
|
23 Jun 2021 |
DARZALEX® (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma
|
|
23 Jun 2021 |
ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma
|
|
22 Jun 2021 |
Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody Candidate AUG-3387 for Clinical Development Against COVID-19
|
|
22 Jun 2021 |
Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford
|
|
22 Jun 2021 |
Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
|
|
22 Jun 2021 |
Prestige Biopharma’s First-in-Class Pancreatic Cancer Treatment, PBP1510, Receives Approval for Clinical Trial in France
|
|
22 Jun 2021 |
LEO Pharma announces European Commission approval of Adtralza® (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis
|
|
22 Jun 2021 |
Xentria Announces the Initiation of a Clinical Trial for XTMAB-16 for the Treatment of Sarcoidosis
|
|
22 Jun 2021 |
Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
|
|
22 Jun 2021 |
GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab
|
|
18 Jun 2021 |
Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate
|
|
17 Jun 2021 |
Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab
|
|
17 Jun 2021 |
Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors
|
|
17 Jun 2021 |
BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer
|
|
17 Jun 2021 |
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
|
|
17 Jun 2021 |
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
|
|
17 Jun 2021 |
Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC
|
|
17 Jun 2021 |
Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease
|
|
16 Jun 2021 |
REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2
|
|
16 Jun 2021 |
Aqualung Therapeutics Plans A Phase 0 ARDS Trial for eNAMPT Monoclonal Antibody (Alt-100 mAb) Following Type B FDA Meeting
|
|
15 Jun 2021 |
Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434
|
|
14 Jun 2021 |
Debiopharm's CD37 Antibody Drug Conjugate Shows Promising Phase II Results for the Treatment of B-Cell Malignancies
|
|
14 Jun 2021 |
Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment
|
